Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Conditions

• Diabetes Mellitus, Type 2
• Obesity
• Overweight

Eligibility Criteria

Sex

ALL

Age

18 Years - 99 Years

Healthy Volunteers

Not accepted

Interventions

• Maridebart Cafraglutide — DRUG
  Administered subcutaneously.
• Placebo — DRUG
  Administered subcutaneously.

Study Details

The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity and type 2 diabetes mellitus. Trial 20210182 is extension of trial 20210184 (NCT06858878).

Key Dates

First listed

Jul 6, 2026

Start date

Jul 29, 2026

Status verified

Sep 2026

Primary completion

Dec 26, 2027

Completion

Mar 19, 2028

Study Design

Enrollment

950 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Maridebart Cafraglutide Low Dose Q4W
  Participants who received low dose of maridebart cafraglutide in the parent trial (20210184 \[NCT06858878\]) will continue to receive low dose of maridebart cafraglutide subcutaneously (SC) once in 4 weeks (Q4W).
• Experimental: Maridebart Cafraglutide Medium Dose Q4W
  Participants who received medium dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive medium dose of maridebart cafraglutide SC Q4W.
• Experimental: Maridebart Cafraglutide Medium dose Q8W
  Participants who received medium dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive medium dose of maridebart cafraglutide SC once in 8 weeks (Q8W).
• Placebo Comparator: Placebo Q4W (Received Medium Dose Maridebart Cafraglutide in Parent Trial)
  Participants who received medium dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive placebo SC Q4W.
• Experimental: Maridebart Cafraglutide High Dose Q4W
  Participants who received high dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive high dose of maridebart cafraglutide SC Q4W.
• Experimental: Maridebart Cafraglutide High Dose Q8W
  Participants who received high dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive high dose of maridebart cafraglutide SC Q8W.
• Placebo Comparator: Placebo Q4W (Received High Dose Maridebart Cafraglutide in Parent Trial)
  Participants who received high dose of maridebart cafraglutide in the parent trial will be re-randomized in this trial to receive placebo SC Q4W.
• Experimental: Maridebart Cafraglutide High Dose Q4W (Received Placebo in the Parent Trial)
  Participants who received placebo in the parent trial will receive high dose of maridebart cafraglutide SC Q4W. Prior to initiating the assigned high dose, participants will undergo a dose-escalation phase gradually increasing doses.
• Experimental: Maridebart Cafraglutide Low Dose Q4W(Received Very Low Dose Maridebart Cafraglutide in Parent Trial)
  Participants who permanently de-escalated to very low dose of maridebart cafraglutide in the parent trial will receive low dose of maridebart cafraglutide SC Q4W.

Primary Outcome Measure

Percent Change in Body Weight from Baseline of the Parent Trial (20210184) [ Time Frame: Baseline of parent trial (20210184) to Week 48 of current trial ]

Central Contacts

• Amgen Call Center
  866-572-6436
  [email protected]

Locations (27)

Find similar trials in Gilbert, AZ

Related Studies

• Investigating the Impact of Obesity on Pubertal Development in Girls
  Recruiting · National Institute of Environmental Health Sciences (NIEHS) · Research Triangle Park, North Carolina
• Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis
  Not Yet Recruiting · Keith Pereira, MD: · St Louis, Missouri
• Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
  Recruiting · The University of Texas Health Science Center at San Antonio · San Antonio, Texas
• Inflammation, Diabetes, Ethnicity and Obesity Cohort
  Recruiting · University of California, San Francisco · San Francisco, California